Immune checkpoint inhibitors of tumors mainly inhibit programmed cell death protein (PD) 1 and cytotoxic T lymphocyte-associated protein (CTLA) 4 are currently the primary approach to tumor immunotherapy (51). The gene discussed is RPL17; the disease is neoplasm.